Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Eileen Ha

Psychiatry Anchorage, AK Doctor of Osteopathy

NPI 1760417208 CMS profile 260939

3260 Providence Dr, Suite 422, Anchorage, AK 99508

Open in the dashboard

General payments

$575

12 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Eileen Ha of Anchorage, AK is reported in the CMS Open Payments database as having received $575 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $18 1
2022 General $126 1
2020 General $28 1
2019 General $403 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eileen Ha
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Eileen Ha were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Eileen Ha Psychiatry median Middle half National median
2019 $403 $184 $59–$605 $163
2020 $28 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $126 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $18 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Neuronetics, Inc. $545 11 payments
  2. Allergan Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $545 11 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2024
  1. NEUROSTAR TMS THERAPY $401 9 payments
  2. NEUROSTAR TMS THERAPY SYSTEM Neurostar Tms Therapy System $126 1 payment
  3. VRAYLAR $30 1 payment
  4. Neurostar TMS Therapy System Neurostar Tms Therapy System $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

524

Median for Psychiatry: 574

Drug cost

$52,418

Median for Psychiatry: $27,624

Branded share of claims

23.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 12 $37,304
Chlorpromazine Hcl Generic 53 $2,249
Bupropion Xl Bupropion Hcl Brand 27 $2,008
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 13 $1,919
Divalproex Sodium Er Divalproex Sodium Brand 25 $1,349
Lamotrigine Generic 47 $1,305
Aripiprazole Generic 45 $965
Venlafaxine Hcl Er Venlafaxine Hcl Brand 33 $897
Buspirone Hcl Generic 26 $791
Zolpidem Tartrate Generic 27 $765

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$32,295

Medicare's payments for the services billed

Medicare patients

39

Average age 68

Services billed

273

28 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 69%
High blood pressure 56%
Arthritis 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record